Več o izdelku femidoc® Utipro® Plus
za strokovno javnost
Izdelek femidoc® Utipro® Plus je medicinski pripomoček v kapsulah, zasnovan za preprečevanje in obvladovanje ponavljajočih se vnetij sečil. S primarnim mehanskih delovanjem v črevesju zmanjšuje intestinalno bakterijsko obremenitev z uropatogeno E. coli, ki je glavni povzročitelj ponavljajočega se cistitisa. Predstavlja alternativo in podporo antibiotičnemu zdravljenju.
Podprto s strani stroke
Izdelek priporočajo mednarodno priznani strokovnjaki s področja urologije, ginekologije, geriatrije in splošne medicine.
Mehanizem delovanja
Izdelek ima primarno delovanje v črevesju in sekundarno v sečilih. Deluje mehansko, tako da zmanjšuje razmnoževanje uropatogenih bakterij in posledično zmanjšuje tveganje za okužbo sečil.
Pogosta vprašanja
Klinične študije kažejo, da femidoc® Utipro® Plus izboljša simptome cistitisa v 5 dneh zdravljenja in zmanjša potrebo po antibiotikih (1).
Da, terapija se lahko po potrebi ponavlja v ciklih. Klinična praksa kaže pozitivne učinke dolgotrajnega jemanja na preprečevanje ponovitev okužb sečil (2). Dolgotrajno jemanje do 9 mesecev nima znanih stranskih učinkov.
Da, izdelek nima znanih interakcij z zdravili.
Ne, glavna učinkovina, ksiloglukan, se v prebavnem traktu ne presnovi in doseže črevesno steno intaktna.
Ne, film iz ksiloglukana-geloze predstavlja selektivno pregrado, ki krepi in posnema obstoječo črevesno sluznico ter ne vpliva na absorpcijo hranil ali zdravil.
Ne, ksiloglukan-gelozni film ne moti delovanja komenzalnih bakterij ali učinkovanja probiotikov.
Vnos hrane ne vpliva na učinkovitost izdelka, zato se kapsule lahko vzame s hrano ali brez.
Priporoča se jemanje izdelka po priloženih navodilih. Kapsulo je mogoče odpreti in vsebino zmešati z vodo ali hrano, vendar organoleptične lastnosti (okus in vonj) praška morda ne bodo prijetne za neposredno zaužitje. Izdelek kljub temu ohrani učinkovitost.
Da. Izdelek femidoc® Utipro® Plus vsebuje zanemarljivo količino sladila sukroze.
Da, izdelek femidoc® Utipro® Plus je primeren tudi za paciente s sočasno prisotnostjo bolezni črevesja.
1. Garcia-Larrosa, A.; Alexe, O. Efficacy and Safety of a Medical Device versus Placebo in the Early Treatment of Patients with Symptoms of Urinary Tract Infection: A Randomized Controlled Trial. Clin. Microbiol. 2016, 5, 1
2. Kostev K, Cai T. Cystitis and Utipro ® Plus: Real-World Evidence. Healthcare. 2023; 11(18):2564.
Znanost v ozadju
Izdelek je registriran medicinski pripomoček, podprt z vrsto kliničnih študij in metaanalizo. Vključen je v strokovne smernice Švicarskega združenja ginekologov in porodničarjev (SSGO, 2020) kot ne-antibiotični pristop za zdravljenje akutnih in ponavljajočih se nezapletenih okužb sečil.
| Type of evidence | Authors | Title | Summary |
|---|---|---|---|
|
Guidelines |
Betschart C. et al., 2020 |
Guideline of the Swiss Society of Gynaecology and Obstetrics (SSGO) on acute and recurrent urinary tract infections in women, including pregnancy |
Utipro® Plus among the antibiotic-free approaches for the treatment of acute and recurrent uncomplicated UTIs. |
|
A Systematic |
Cai T. et al., 2022 |
Xyloglucan, Hibiscus and Propolis in the Management of Uncomplicated Lower Urinary Tract Infections |
A medical device containing xyloglucan, hibiscus and propolis is superior to comparator regimens in terms of clinical effectiveness in adult women with microbiologically confirmed or clinical suspicion of uncomplicated cystitis and is associated with a high patient compliance. |
|
Multicentre, randomised, parallel group, double-blind, phase IV study |
Costache R. C. et al., 2019 |
Xyloglucan-Gelose combination versus Placebo as Adjuvant Therapy to First line Antimicrobials for Uncomplicated Urinary Tract Infection in Adults |
The combination of xyloglucan and gelose was safe, well tolerated and reduced bacteriological and symptomatic parameters, in particular urinary incontinence and urgency of micturition. |
|
Randomized placebo-controlled clinical trial |
Salvatorelli N. et al., 2016 |
A new approach to the treatment of uncomplicated cystitis |
The medical device can help in preventing the recurrence of uncomplicated cystitis as well as helps to reduce antibiotic use in management of urinary tract infection in women. |
|
Randomized double-blind, placebo-controlled trial |
Garcia-Larrosa A. et al., 2016 |
Efficacy and safety of a medical device versus placebo in the early treatment of patients with symptoms of urinary tract infection |
The medical device was more effective than placebo in improving UTI symptoms and it reduced the need for antibiotic rescue. |
|
Observational, prospective, and multicenter study |
Ortega P. et al., 2022 |
Clinical Experience with a Medical Device Containing Xyloglucan, Hibiscus, and Propolis for the Control of Acute Uncomplicated Urinary Tract – like Symptoms |
The objective of the study was to evaluate the efficacy of a medical device in clinical practice with a cohort of women from Switzerland, paying special attention to the history of UTIs. A total of 84 women (81.6%) did not require an additional consultation, whereas 17 (16.5%) required a second one. |
|
Observational, prospective study |
T. Cai et al., 2019 |
Xyloglucan, hibiscus and propolis to reduce symptoms and antibiotics use in recurrent UTIs: a prospective study |
This medical device is able to improve quality of life in women with rUTIs, and to reduce recurrence rate and the use of antibiotics. |
|
Observational, retrospective, cross-sectional study |
Kostev K. and Cai T., 2023 |
Cystitis and Utipro® Plus: Real-World Evidence |
The use of Utipro® Plus is able to decrease UTI recurrence and can lead to the reduction of antibiotic prescriptions and disease burden in individuals affected by uncomplicated cystitis. |
|
Review |
Guglietta A., 2017 |
Recurrent urinary tract infections in women: risk factors, etiology, pathogenesis and prophylaxis |
Review of the role of alternative non-antibiotic based approaches, such as mechanical barrier protection of the intestinal mucosa in UTI management. |
|
Review |
Rodriguez
Mañas L., 2020
|
Urinary tract infections in the elderly: a review of disease characteristics and current treatment options |
New treatment strategies that offer a safe and effective non-antimicrobial means of managing UTIs could have an important role in the elderly. |
|
Review |
Piqué N. et al., 2018 |
Xyloglucan, a plant polymer with barrier protective properties over the mucous membranes: an overview |
Xyloglucan, endowed with film-forming protective barrier properties, is a safe no-pharmacological alternative for the management of different diseases. |
|
In vivo study |
Olier M. et al., 2017 |
Evaluation of reticulated gelatine hibiscus propolis against intestinal commensal species commonly associated with urinary tract infections |
The medical device alters the intestinal niche occupied by uropathogens such as E. coli. |
|
In vivo study |
Esposito E. et al., 2020 |
Efficacy of Xyloglucan against
Escherichia coli Extraintestinal Urinary Tract Infection: An in vivo Study
|
The study supports the potential beneficial effect of xyloglucan or xyloglucan-gelose in preventing extraintestinal UTIs by means of reducing E. coli colonies. |
|
In vivo study |
Esposito E. et al., 2018 |
Protective Effects of Xyloglucan in Association with the Polysaccharide Gelose in an Experimental Model of Gastroenteritis and Urinary Tract Infections |
Rats were infected by oral administration of Salmonella enterica and Enterococcus hirae. The compound reduced the number of bacterial colonies in the urinary tract favoring elimination by feces. The results obtained in the present study suggest that the protective barrier properties of xyloglucan plus gelose allow the prevention of GE and UTI in models of infections in rats. |
|
In vitro study |
Fraile B. et al., 2017 |
Xyloglucan, hibiscus and propolis for the prevention of urinary tract infections. Results of in vitro studies |
Xyloglucan, hibiscus and propolis did not alter E. coli cell integrity in intestinal and uroepithelial cell models and were devoid of antibacterial activity. The non-pharmacological barrier properties of these components confirm the role of the medical device for the management of urinary tract infections. |
|
In vitro study |
De Servi B. et al., 2016 |
Efficacy of a medical device containing xyloglucan gelatin against Escherichia coli invasion of intestinal epithelial cells: results of an in vitro study |
The medical device creates a protective physical barrier on epithelial intestinal cells in vitro, which reduces the settling of E coli reservoirs. |
|
Case reports |
Cai T., Konstantidinis C., Ward S., 2021 |
A non-pharmacological approach to the treatment of urinary tract infections: case reports with Utipro® Plus |
Publication on case series referring about the benefits of Utipro® Plus in some challenging cases of urinary infections. In this new publication, the product has proven its usefulness as a non-pharmacological approach in recurrent UTIs, thus allowing a rational use of antibiotics. |
